Home » About us

About us


  • Privately-held clinical stage Montreal-based biotechnology company
  • Engaged in the discovery and development of therapeutic mAbs against highly-disease tissue specific novel clinically-relevant targets
  • Currently, having one program with Phase I data
  • Portfolio of highly-specific, novel and clinically-relevant targets using the proprietary STAR technology
  • Exploiting a powerful a proprietary target discovery technology with the potential to expand pipeline
  • Established strategic partnerships to to access mAb generation, humanization, antibody drug conjugates, and CHO production technologies
  • Seasoned management and multi-disciplinary discovery and early-stage development team
  • Unencumbered pipeline with the potential for selected strategic partnerships on therapeutic mAbs